Clinical trials: White Blood Cells
Metabolism, Inborn Errors, Granulomatous Disease, Chronic
Study of Total Body Irradiation and Fludarabine Followed By Allogeneic Peripheral Blood Stem Cell or Bone Marrow Transplantation in Combination With Cyclosporine and Mycophenolate Mofetil in Patients With Inherited Disorders
OBJECTIVES: I. Determine the safety of total body irradiation and fludarabine followed by allogeneic peripheral blood stem cell or bone marrow transplantation in combination with cyclosporine and mycophenolate mofetil for…
- Trial name
- NCT00010361
- Testing
- cyclosporine, fludarabine, mycophenolate mofetil
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Fred Hutchinson Cancer Center
Dactinomycin Adverse Reaction, Bone and Joint Infection
Pharmacokinetics and Toxicodynamics of Daptomycin in Bone and Joint Infections
the aim of this study is to investigate the relationship between exposure to daptomycin and the occurrence of muscle toxicity or eosinophilic pneumonia in patients treated with daptomycin for bone and joint infection
- Trial name
- PKTOXDAP (NCT04933344)
- Testing
- patients having had BJI or PJI treated with daptomycin
- Where
- France
- Volunteers
- 1,130 people
- Sponsor
- Hospices Civils de Lyon
Eosinophilic Gastritis, Eosinophilic Gastroenteritis
A Study of AK002 in Patients With Eosinophilic Gastritis and/or Eosinophilic Gastroenteritis
This is a Phase 2, double-blind, randomized, placebo-controlled study to assess the effects of AK002, given monthly for 4 doses.
- Trial name
- ENIGMA (NCT03496571)
- Testing
- AK002
- Where
- 21 sites in United States
- Volunteers
- 65 people
- Sponsor
- Allakos Inc.
Hereditary Haemorrhagic Telangiectasia
Immunological Effects of Iron Supplementation in HHT Disease
Hereditary haemorrhagic telangiectasia (HHT), is a rare genetic vascular disorder with autosomal dominant inheritance. Its prevalence is estimated at approximately 1 in 6,000 individuals in France.
- Trial name
- Fer&RO (NCT07111598)
- Testing
- Blood test at D0, Blood test at D+3 months
- Where
- France
- Volunteers
- 155 people
- Sponsor
- Hospices Civils de Lyon
Critical Care
Evaluation of Cyto-chex Tubes for the Measurement of Monocyte Expression of Human Leukocyte Antigen - DR Isotype (HLA-DR) Molecules by Flow Cytometry
The expression of mHLA-DR, measured by flow cytometry, is today the reference marker to guide immunostimulatory therapies (IFN-γ) in the most severely immunocompromised patients.
- Trial name
- CHEX-DR (NCT05546632)
- Testing
- Blood sampling
- Where
- France
- Volunteers
- 40 people
- Sponsor
- Hospices Civils de Lyon
Colorectal Cancer, Colon Cancer
Histocompatibility Leukocyte Antigen (HLA)-A*2402 Restricted Peptide Vaccine Therapy in Patients With Colorectal Cancer
The purpose of this study is to evaluate the safety and time to progression of HLA-A*2402 restricted epitope peptides RNF43, TOMM34, VEGFR1 and VEGFR2 emulsified with Montanide ISA 51 in combination with Tegafur/Uracil/Folinate…
- Conditions
- Colorectal Cancer, Colon Cancer, Rectal Cancer
- Trial name
- NCT00677287
- Testing
- RNF43, TOMM34, VEGFR1 and VEGFR2
- Where
- Japan
- Volunteers
- 14 people
- Sponsor
- Tokyo University
Cancer
Controling Intestinal Colonization With Extended Spectrum ß-Lactamase Producing Enterobacteriaceae ESBL-E
Rapid and rational health-care interventions are of great importance to efficiently combat the emergence of resistant and virulent bacteria. In recent years, spread of ESBL-E on a global level has been observed.
- Trial name
- CLEAR (NCT01931592)
- Testing
- ESBL eradication regimen
- Where
- 2 sites in Germany
- Volunteers
- 29 people
- Sponsor
- Maria J.G.T. Vehreschild
Children Under 3 Months of Age With Fever
Diagnostic Performance of a Combination of Leukocyte Cell Surface Markers in Predicting the Risk of Severe Bacterial Infection in Febrile Children Under Three Months of Age in the Emergency Department: a Pilot Study.
Fever is a frequent reason for emergency department (ED) visits in infants under 3 months of age. Although viral infections are the most common etiologies, the prevalence of severe bacterial infections (SBI) is high (10%).
- Trial name
- CYTOFEB (NCT06618989)
- Testing
- Blood sampling and follow-up call
- Where
- 2 sites in France
- Volunteers
- 180 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Neutropenia, Sarcoma
Combination Chemotherapy in Treating Patients With Newly Diagnosed Metastatic Ewing's Sarcoma or Primitive Neuroectodermal Tumor
Phase II trial to study the effectiveness of combination chemotherapy in treating patients with newly diagnosed metastatic Ewing's sarcoma or primitive neuroectodermal tumor.
- Trial name
- NCT00002643
- Testing
- filgrastim, amifostine trihydrate, cyclophosphamide
- Where
- 49 sites in United States, Australia and 3 more
- Volunteers
- 130 people
- Sponsor
- National Cancer Institute (NCI)
Severe Eosinophilic Asthma
STEP: Phase IIIb Study of Benralizumab to Step-down Maintenance Therapy in Patients With Severe Eosinophilic Asthma
This is a prospective, multi-center, single-arm Phase 3b study designed to evaluate the potential benefit to patients if benralizumab treatment could enable reduction in asthma maintenance controllers while allowing patients to…
- Trial name
- STEP (NCT06465485)
- Testing
- Benralizumab
- Where
- 74 sites in China
- Volunteers
- 504 people
- Sponsor
- AstraZeneca
Severe Asthma
BRazilian Asthmatics Patients EOSinophilic Profile (BRAEOS)
Asthma is a complex and heterogeneous disease. Severe asthma is recognised as a major unmet need that poses a great burden on the healthcare system.
- Trial name
- BRAEOS (NCT03925415)
- Where
- 6 sites in Brazil
- Volunteers
- 414 people
- Sponsor
- AstraZeneca
Diffuse Large B Cell Lymphoma, Neutropenia, Febrile
Multicenter Prospective Registry Study of Diffuse Large B Cell Lymphoma
This study was designed to review clincal outcomes of Diffuse Large B Cell Lymphoma (DLBCL) treated with R-CHOP chemotherapy in the era of pegylated-filgrastim.
- Trial name
- NCT02474550
- Where
- 24 sites in South Korea
- Volunteers
- 1,000 people
- Sponsor
- Ajou University School of Medicine
Osteoarthritis Thumb
Single Blinded First CMC Osteoarthritis Treatment
Single blinded PRP vs. Corticosteroid vs. Placebo (normal saline) intra-articular injection for basal joint arthritis.
- Trial name
- NCT03196310
- Testing
- Platelet Concentrate, Corticosteroid injection, Normal Saline
- Where
- United States
- Volunteers
- 74 people
- Sponsor
- Kettering Health Network
Eosinophilic Esophagitis
a4b7 Integrin in Eosinophilic Esophagitis
The overall objective of this preclinical study is to further the investigators mechanistic understanding of the role that the α4β7 and mucosal addressin cell adhesion molecule (MAdCAM-1) pathway plays in mediating eosinophil…
- Trial name
- NCT02546219
- Testing
- Eosinophil isolation and characterization.
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Massachusetts General Hospital
Acute Myeloid Leukemia
Fractionated Gemtuzumab Ozogamicin Followed by Non-engraftment Donor Leukocyte Infusions for Relapsed/Refractory Acute Myeloid Leukemia
This study includes patients with relapsed acute leukemia who have previously been treated with standard treatment that is still present and there is no curative treatment option available.
- Trial name
- NCT03374332
- Testing
- Gemtuzumab Ozogamicin (GO), Donor Leukocytes
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Brown University
Esophageal Cancer
Human Leukocyte Antigen (HLA) - A*2402 Restricted Peptide Vaccine Therapy in Patients With Advanced Esophageal Cancer
The purpose of this study it to evaluate the safety and immune response of peptides (URLC10) emulsified with Montanide ISA51 in treating patients with unresectable, advanced or recurrent esophageal cancer.
- Trial name
- NCT00753844
- Testing
- URLC10
- Where
- Japan
- Volunteers
- 7 people
- Sponsor
- Kinki University
Infection, Neutropenia
Anidulafungin in Treating Immunocompromised Children With Neutropenia
RATIONALE: Anidulafungin may be effective in preventing fungal infections in immunocompromised children who have neutropenia. PURPOSE: This phase I/II trial is studying the side effects of anidulafungin and to see how well it…
- Conditions
- Infection, Neutropenia, Unspecified Childhood Solid Tumor, Protocol Specific
- Trial name
- NCT00068471
- Testing
- anidulafungin
- Where
- 5 sites in United States
- Sponsor
- National Cancer Institute (NCI)
Asthma, COPD
Asthma, Inflammation and G Protein-coupled Receptors (GPCR)
The G protein-coupled receptors (GPCRs) are a family of proteins expressed at the cell membrane. They are composed of 380 members involved in the important functions of the organism and are privileged therapeutic targets.Their…
- Trial name
- NCT00793676
- Testing
- spirometry, blood test
- Where
- 5 sites in France
- Volunteers
- 205 people, healthy volunteers welcome
- Sponsor
- University Hospital, Strasbourg, France
Breast Cancer, Transcriptomes
Transcriptomes Breast, Ovarian and Leukocyte Hereditary Genes Predisposing to Breast and / or Ovarian Cancer
This is a case-control study of molecular diagnostics. This study requires two steps: The first part of the study will be conducted on a population of 20 women without breast cancer and, or ovarian family (Healthy Volunteers…
- Conditions
- Breast Cancer, Transcriptomes, Molecular Diagnostic, Ovarian Cancer
- Trial name
- CASOHAR (NCT02560818)
- Testing
- collection of a blood sample and breast and ovarian tissue, use of a previous blood collection for patients
- Where
- France
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Centre Francois Baclesse
Eosinophilic Asthma
Randomised Clinical Trial to Investigate Efficacy and Safety of Benralizumab 30 mg SC as an add-on Therapy in Uncontrolled Eosinophilic Asthma Patients Treated With Medium-dose ICS-LABA Compared to Conventional Escalation to High-dose ICS-LABA Treatment
This study evaluates the efficacy and safety of benralizumab as an add-on therapy in uncontrolled eosinophilic asthma participants treated with medium-dose ICS-LABA compared to the conventional treatment step of escalation of…
- Trial name
- BRISOTE (NCT06750289)
- Testing
- ICS-LABA, benralizumab
- Where
- 86 sites in United States, Bulgaria and 11 more
- Volunteers
- 130 people
- Sponsor
- AstraZeneca
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.